Condition: Low-Grade Serous Ovarian Cancer · Sponsor: Memorial Sloan Kettering Cancer Center
The researchers are doing this study to find out whether the combination of avutometinib, defactinib, and letrozole is an effective treatment for people with low-grade serous ovarian cancer (LGSOC). The researchers will also look at the safety of this combination.
This description comes directly from the study's public registry record.
Rachel Grisham, MD · 646-888-4653 · medgmoclinicaltrials@mskcc.org
Chrisann Kyi, MD · 646-888-4221
Always discuss trial participation with your own doctor first.
| Emory Winship Cancer Institute | Atlanta, Georgia, United States | Recruiting |
| Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) | Basking Ridge, New Jersey, United States | Recruiting |
| Memorial Sloan Kettering Monmouth (Limited Protocol Activities) | Middletown, New Jersey, United States | Recruiting |
| Memorial Sloan Kettering Bergen (Limited Protocol Activities) | Montvale, New Jersey, United States | Recruiting |
| Memorial Sloan Kettering Suffolk -Commack (Limited Protocol Activities) | Commack, New York, United States | Recruiting |
| Memorial Sloan Kettering Westchester (Limited Protocol Activities) | East White Plains, New York, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center | New York, New York, United States | Recruiting |
| Memorial Sloan Kettering Nassau (Limited Protocol Activities) | Uniondale, New York, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06394804